Search

Your search keyword '"Valteau-Couanet, D."' showing total 17 results

Search Constraints

Start Over You searched for: Author "Valteau-Couanet, D." Remove constraint Author: "Valteau-Couanet, D." Topic busulfan Remove constraint Topic: busulfan
17 results on '"Valteau-Couanet, D."'

Search Results

1. Busulfan-Melphalan followed by autologous stem cell transplantation in patients with high-risk neuroblastoma or Ewing sarcoma: an exposed-unexposed study evaluating the clinical impact of the order of drug administration.

2. Busulfan-melphalan in high-risk neuroblastoma: the 30-year experience of a single institution.

3. Iron Overload Exacerbates Busulfan-Melphalan Toxicity Through a Pharmacodynamic Interaction in Mice.

4. Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial.

5. Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results.

6. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring.

7. High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: high toxicity and lack of efficacy.

8. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).

9. Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma.

10. Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations.

11. Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure.

12. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation.

13. Chronopharmacology of high-dose busulfan in children.

14. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children.

15. Is 600 mg/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation?

16. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study.

Catalog

Books, media, physical & digital resources